MX2016011837A - Composiciones de inhibidores de la dopa decarboxilasa. - Google Patents

Composiciones de inhibidores de la dopa decarboxilasa.

Info

Publication number
MX2016011837A
MX2016011837A MX2016011837A MX2016011837A MX2016011837A MX 2016011837 A MX2016011837 A MX 2016011837A MX 2016011837 A MX2016011837 A MX 2016011837A MX 2016011837 A MX2016011837 A MX 2016011837A MX 2016011837 A MX2016011837 A MX 2016011837A
Authority
MX
Mexico
Prior art keywords
compositions
decarboxylasa
dopa
inhibitors
disease
Prior art date
Application number
MX2016011837A
Other languages
English (en)
Spanish (es)
Inventor
Oron Yacoby-Zeevi
Original Assignee
Neuroderm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53488380&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016011837(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neuroderm Ltd filed Critical Neuroderm Ltd
Publication of MX2016011837A publication Critical patent/MX2016011837A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2016011837A 2014-03-13 2015-03-12 Composiciones de inhibidores de la dopa decarboxilasa. MX2016011837A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461952477P 2014-03-13 2014-03-13
US201461990967P 2014-05-09 2014-05-09
PCT/IL2015/050258 WO2015136538A1 (en) 2014-03-13 2015-03-12 Dopa decarboxylase inhibitor compositions

Publications (1)

Publication Number Publication Date
MX2016011837A true MX2016011837A (es) 2017-04-27

Family

ID=53488380

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016011837A MX2016011837A (es) 2014-03-13 2015-03-12 Composiciones de inhibidores de la dopa decarboxilasa.

Country Status (19)

Country Link
US (5) US10022320B2 (enExample)
EP (3) EP3116475B1 (enExample)
JP (2) JP6591995B2 (enExample)
CN (1) CN106413754B (enExample)
AU (1) AU2015228369B2 (enExample)
BR (1) BR112016021034A8 (enExample)
CA (1) CA2942244C (enExample)
DK (2) DK3116475T3 (enExample)
ES (2) ES2836325T3 (enExample)
FI (1) FI3777833T3 (enExample)
HR (2) HRP20201948T1 (enExample)
HU (2) HUE064818T2 (enExample)
IL (1) IL247668B (enExample)
MX (1) MX2016011837A (enExample)
PL (2) PL3116475T3 (enExample)
PT (2) PT3116475T (enExample)
RS (1) RS65060B1 (enExample)
RU (1) RU2684105C2 (enExample)
WO (1) WO2015136538A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2559083C9 (ru) 2009-05-19 2016-01-20 Неуродерм Лтд Композиции для непрерывного введения ингибиторов допа-декарбоксилазы
CN110123743A (zh) 2010-11-15 2019-08-16 纽罗德姆有限公司 L-多巴、多巴脱羧酶抑制剂、儿茶酚-o-甲基转移酶抑制剂及其组合物的连续施用
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
EP3116475B1 (en) 2014-03-13 2020-11-04 Neuroderm Ltd Dopa decarboxylase inhibitor compositions
JP6491747B2 (ja) 2015-09-30 2019-03-27 デューク・ユニヴァーシティ 磁気共鳴画像法用の造影剤
WO2018154447A1 (en) * 2017-02-21 2018-08-30 Neuroderm Ltd Dopa decarboxylase inhibitor compositions
UY38473A (es) 2018-11-15 2020-06-30 Abbvie Inc Formulaciones farmacéuticas para una administración subcutánea
WO2020178810A1 (en) * 2019-03-04 2020-09-10 Neuroderm, Ltd. Pharmaceutical compositions comprising levodopa amide derivatives and uses thereof
CN111701024B (zh) * 2020-05-26 2022-05-24 上海京新生物医药有限公司 一种左旋多巴制剂及其制备方法及其应用
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
CN113396897B (zh) * 2021-07-26 2022-06-07 苏州华测生物技术有限公司 一种稳定生物基质中卡比多巴/左旋多巴的方法
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3769424A (en) 1970-10-01 1973-10-30 Merck & Co Inc Composition and method of treating dopamine deficiency in brain tissue
AU6889274A (en) 1973-05-17 1975-11-20 Astra Laekemedel Ab Treatment of neurological disorders
US3936495A (en) 1973-11-27 1976-02-03 Merck & Co., Inc. Purification process
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4241082A (en) 1977-09-02 1980-12-23 Sankyo Company Limited Agents for promoting reproductive ability of domestic animals
JPS5450700A (en) 1977-09-28 1979-04-20 Sankyo Co Glazing agent of animal leather
JPS6021570B2 (ja) 1978-07-04 1985-05-28 三共株式会社 ド−パ類の高濃度製剤の製法
JPS56115749A (en) 1980-02-18 1981-09-11 Sagami Chem Res Center Dopa derivative
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4642316A (en) 1985-05-20 1987-02-10 Warner-Lambert Company Parenteral phenytoin preparations
ES2042520T3 (es) 1986-06-10 1993-12-16 Chiesi Farma Spa Composiciones farmaceuticas que contienen el ester metilico de levodopa, preparacion y aplicaciones terapeuticas del mismo.
US4832957A (en) 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US4684666A (en) 1986-08-19 1987-08-04 Haas Pharmaceuticals, Inc. Stabilized liquid analgesic compositions
IT1226902B (it) 1988-07-12 1991-02-21 Mini Ricerca Scient Tecnolog Processo per la sintesi del levodopa
US4963568A (en) 1989-05-31 1990-10-16 Abbott Laboratories Dopamine agonists
US5350769A (en) 1990-10-30 1994-09-27 Ss Pharmaceutical Co., Ltd. Antiinflammatory gel preparation
US5877176A (en) 1991-12-26 1999-03-02 Cornell Research Foundation, Inc. Blocking induction of tetrahydrobiopterin to block induction of nitric oxide synthesis
CA2143070C (en) 1994-02-22 2001-12-18 Pankaj Modi Oral controlled release liquid suspension pharmaceutical formulation
ES2211904T3 (es) 1995-05-26 2004-07-16 Pfizer Inc. Combinaciones para el tratamiento del parkinsonismo que contienen antagonistas selectivos de nmda.
GB9523833D0 (en) 1995-11-22 1996-01-24 Boots Co Plc Medical treatment
US6746688B1 (en) 1996-10-13 2004-06-08 Neuroderm Ltd. Apparatus for the transdermal treatment of Parkinson's disease
IL119417A (en) 1996-10-13 2003-02-12 Moshe Kushnir Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease
US5861423A (en) 1997-02-21 1999-01-19 Caldwell; William Scott Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
US6245917B1 (en) 1998-03-20 2001-06-12 Warner-Lambert Company Crystalline sodium phenytoin monohydrate
US7201923B1 (en) 1998-03-23 2007-04-10 General Mills, Inc. Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles
IL139298A0 (en) 1998-05-15 2001-11-25 Warner Lambert Co Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same
US6274168B1 (en) 1999-02-23 2001-08-14 Mylan Pharmaceuticals Inc. Phenytoin sodium pharmaceutical compositions
US6716452B1 (en) 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
WO2000054773A1 (en) 1999-03-12 2000-09-21 Nitromed, Inc. Dopamine agonists in combination with nitric oxide donors, compositions and methods of use
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US7479498B2 (en) 1999-08-23 2009-01-20 Phoenix Biosciences, Inc. Treatments for viral infections
US6348965B1 (en) 1999-09-24 2002-02-19 Henry Palladino Solid state fluorescence and absorption spectroscopy
SE0001151D0 (sv) 2000-03-31 2000-03-31 Amarin Dev Ab Method for producing a controlled-release composition
US20020028799A1 (en) 2000-07-06 2002-03-07 Naylor Alasdair Mark Treatment of male sexual dysfunction
GB0017387D0 (en) 2000-07-14 2000-08-30 Pfizer Ltd Novel enzyme
US20020099013A1 (en) 2000-11-14 2002-07-25 Thomas Piccariello Active agent delivery systems and methods for protecting and administering active agents
US20030119714A1 (en) 2000-12-15 2003-06-26 Naylor Alasdair Mark Treatment of male sexual dysfunction
EP1345925B1 (en) 2000-12-21 2006-05-17 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
IL159812A0 (en) 2001-07-12 2004-06-20 Teva Pharma Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester in a controlled release core
BRPI0213425B8 (pt) 2001-10-19 2021-05-25 Idexx Lab Inc composições injetáveis para a liberação controlada de composto farmacologicamente ativo, usos do referido composto e método para suas preparações
WO2003050261A2 (en) 2001-12-10 2003-06-19 Bristol-Myers Squibb Company (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial f1f0 atp hydrolase
ES2189682B1 (es) 2001-12-11 2004-04-01 Laboratorios Del Dr. Esteve, S.A. Preparacion bebible que comprende ketoprofeno y su empleo en el tratamiento de procesos que cursan con fiebre, inflamacion y/o dolor, en un colectivo de animales, de forma simultanea.
WO2003084514A1 (en) 2002-04-11 2003-10-16 Ranbaxy Laboratories Limited Controlled release pharmaceutical compositions of carbidopa and levodopa
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
EP1551829B1 (de) 2002-10-10 2010-04-07 Morphochem Aktiengesellschaft Für Kombinatorische Chemie Neue verbindungen mit antibakterieller aktivität
EP1596808A4 (en) 2003-02-07 2007-04-04 Yissum Res Dev Co L-DOPA AMID DERIVATIVES AND THEIR USE
WO2005035088A2 (en) 2003-07-18 2005-04-21 Baxter International, Inc. Method for preparing small spherical by controlled phase separation
US7589233B2 (en) 2003-07-29 2009-09-15 Signature R&D Holdings, Llc L-Threonine derivatives of high therapeutic index
US8173840B2 (en) 2003-07-29 2012-05-08 Signature R&D Holdings, Llc Compounds with high therapeutic index
GB0319935D0 (en) 2003-08-26 2003-09-24 Cipla Ltd Polymorphs
CN1845728B (zh) * 2003-08-29 2013-06-19 转化医药公司 包含左旋多巴和卡比多巴的药物组合物
JP5160786B2 (ja) * 2003-08-29 2013-03-13 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 医薬組成物及びレボドパ及びカルビドパの使用方法
US20050053669A1 (en) 2003-09-05 2005-03-10 Boehringer Ingelheim International Gmbh Administration form for the oral application of poorly soluble acidic and amphorteric drugs
WO2005041925A2 (en) 2003-10-31 2005-05-12 Alza Corporation Compositions and dosage forms for enhanced absorption
WO2005099678A1 (en) 2004-04-06 2005-10-27 Transform Pharmaceuticals, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
SE0401842D0 (sv) 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
DK1797109T3 (en) 2004-09-09 2016-04-11 Yeda Res & Dev MIXTURES OF POLYPEPTIDES, compositions containing them and methods for their preparation, and uses thereof
WO2006037061A2 (en) 2004-09-28 2006-04-06 Farouk Karoum Compositions and methods of using d-dopa to treat parkinson's disease
CA2582346A1 (en) 2004-10-01 2006-04-13 The Research Foundation Of State University Of New York Morphine and morphine precursors
ATE444746T1 (de) 2005-06-08 2009-10-15 Orion Corp Eine herstellungsmethode von entacapon- enthaltenden granulaten für orale dosierformen
DE102006021872B4 (de) 2006-05-11 2008-04-17 Sanofi-Aventis 4,5-Diphenyl-pyrimidinyl-oxy oder -mercapto substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
RU2484815C2 (ru) 2006-05-31 2013-06-20 Зольвай Фармасьютиклз Гмбх Продолжительное 24-часовое введение в кишечник леводопа/карбидопа
PE20080669A1 (es) 2006-09-08 2008-07-18 Drugtech Corp Composicion de liberacion sostenida que comprende levodopa
CA2606658A1 (en) 2006-10-13 2008-04-13 Mike Tyers Compositions and methods for treating neurological disorders or damage
EP2144663A4 (en) 2007-04-06 2011-06-22 Transform Pharmaceuticals Inc SYSTEMS AND METHODS FOR DISTRIBUTING A FLUID MEDICINE
CL2008003507A1 (es) 2007-11-26 2009-11-27 Neuroderm Ltd Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico.
AU2009211028B2 (en) * 2008-02-06 2013-12-05 Wockhardt Research Centre Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability
CN101669925B (zh) 2008-09-10 2011-08-10 天津药物研究院 干粉吸入剂、其制备方法和用途
WO2010055133A1 (en) 2008-11-14 2010-05-20 Neurosearch A/S Benzimidazole derivatives and their use for modulating the gabaa receptor complex
US20130253056A1 (en) 2009-05-19 2013-09-26 Neuroderm, Ltd. Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same
RU2559083C9 (ru) * 2009-05-19 2016-01-20 Неуродерм Лтд Композиции для непрерывного введения ингибиторов допа-декарбоксилазы
CN101987081B (zh) 2010-07-16 2012-08-08 钟术光 一种控释制剂
KR101187064B1 (ko) 2010-07-18 2012-09-28 주식회사 바이오폴리메드 양이온성 지질, 이의 제조 방법 및 이를 포함하는 세포내 이행성을 갖는 전달체
US10150792B2 (en) 2010-11-08 2018-12-11 Synthonics, Inc. Bismuth-containing compounds, coordination polymers, methods for modulating pharmacokinetic properties of biologically active agents, and methods for treating patients
SI2640370T1 (en) 2010-11-15 2018-08-31 Neuroderm Ltd Weizmann Science Park Compounds for transdermal delivery of active ingredients
CN110123743A (zh) 2010-11-15 2019-08-16 纽罗德姆有限公司 L-多巴、多巴脱羧酶抑制剂、儿茶酚-o-甲基转移酶抑制剂及其组合物的连续施用
BR112013014304A2 (pt) 2010-12-10 2016-07-19 Synagile Corp composições de pró-fármaco levodopa infundíveis subcutaneamente e método de infusão
WO2013061161A2 (en) 2011-10-28 2013-05-02 Green Bcn Consulting Services Sl New combination therapies for treating neurological disorders
TR201204839A2 (tr) * 2012-04-25 2012-12-21 Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. Uzatılmış salım sağlayan levodopa karbıdopa entakapon içeren tablet formülasyonu.
WO2013184646A2 (en) 2012-06-05 2013-12-12 Synagile Corporation Dosing regimens for subcutaneously infusible acidic compositions
WO2013183055A1 (en) 2012-06-05 2013-12-12 Neuroderm Ltd Compositions comprising apomorphine and organic acids and uses thereof
RU2677278C2 (ru) * 2013-03-13 2019-01-16 Неуродерм Лтд Способ лечения болезни паркинсона
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
EP3116475B1 (en) 2014-03-13 2020-11-04 Neuroderm Ltd Dopa decarboxylase inhibitor compositions
MX393568B (es) 2014-10-21 2025-03-24 Abbvie Inc Profarmacos de carbidopa y l-dopa y metodos de uso
RU2018119194A (ru) 2015-11-24 2019-12-25 Нейродерм Лтд. Фармацевтические композиции, содержащие амид леводопы, и их применения
WO2018154447A1 (en) 2017-02-21 2018-08-30 Neuroderm Ltd Dopa decarboxylase inhibitor compositions
WO2019038638A1 (en) 2017-08-21 2019-02-28 Neuroderm Ltd PROCESS FOR PREPARING AMIDE OF PURIFIED LEVODOPA
AR112683A1 (es) 2017-08-21 2019-11-27 Neuroderm Ltd Forma cristalina de base libre de levodopa, su sal de adición y composición farmaceutica que la comprende
WO2019038637A1 (en) 2017-08-21 2019-02-28 Neuroderm Ltd FORMS OF CRYSTALLINE SALT OF LEVODOPA AMIDE AND METHODS OF MAKING AND USING THEM

Also Published As

Publication number Publication date
PT3116475T (pt) 2020-12-15
US10022320B2 (en) 2018-07-17
JP2020011977A (ja) 2020-01-23
EP3777833A1 (en) 2021-02-17
RU2016135952A (ru) 2018-04-13
BR112016021034A2 (pt) 2017-08-15
JP2017507973A (ja) 2017-03-23
HUE064818T2 (hu) 2024-04-28
DK3777833T3 (da) 2023-12-18
WO2015136538A1 (en) 2015-09-17
US20190151233A1 (en) 2019-05-23
AU2015228369A1 (en) 2016-10-27
HRP20201948T1 (hr) 2021-01-22
US20150352212A1 (en) 2015-12-10
CN106413754A (zh) 2017-02-15
PT3777833T (pt) 2024-01-09
HUE052642T2 (hu) 2021-05-28
ES2836325T3 (es) 2021-06-24
IL247668A0 (en) 2016-11-30
AU2015228369B2 (en) 2020-05-21
CN106413754B (zh) 2019-11-29
PL3116475T3 (pl) 2021-02-08
US20210038505A1 (en) 2021-02-11
RS65060B1 (sr) 2024-02-29
EP4299128A2 (en) 2024-01-03
JP6591995B2 (ja) 2019-10-16
FI3777833T3 (fi) 2024-01-03
ES2967693T3 (es) 2024-05-03
EP3116475B1 (en) 2020-11-04
RU2684105C2 (ru) 2019-04-04
US10624839B2 (en) 2020-04-21
JP6770158B2 (ja) 2020-10-14
CA2942244A1 (en) 2015-09-17
DK3116475T3 (da) 2020-12-07
IL247668B (en) 2020-09-30
BR112016021034A8 (pt) 2021-06-29
RU2016135952A3 (enExample) 2018-09-12
US20230240980A1 (en) 2023-08-03
EP3116475A1 (en) 2017-01-18
HRP20231716T1 (hr) 2024-03-15
PL3777833T3 (pl) 2024-03-25
US20260102334A1 (en) 2026-04-16
EP4299128A3 (en) 2024-04-17
CA2942244C (en) 2022-08-23
EP3777833B1 (en) 2023-10-18

Similar Documents

Publication Publication Date Title
EP4299128A3 (en) Dopa decarboxylase inhibitor compositions
CL2019001551A1 (es) Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes
DOP2018000297A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
SA521421115B1 (ar) عقاقير أولية من كربيدوبا وليفودوبا وطرق الاستخدام
CL2015002641A1 (es) Método para el tratamiento de la enfermedad de parkinson.
GT201500293A (es) Composiciones de arni contra el componente c5 del complemento y métodos para su uso
MX2018000577A (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la ret quinasa.
UY34593A (es) Miméticos sintéticos de apelina para el tratamiento de falla cardiaca
CL2016003422A1 (es) Inhibidores de demetilasa-1 específico de lisina
BR112017005693A2 (pt) método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica.
CL2016003423A1 (es) Inhibidores de demetilasa-1 específico de lisina
BR112016019592A8 (pt) Composto, uso de um composto, e, composição farmacêutica
MX2018008050A (es) Agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada con estabilidad endopeptidasa neutral (nep) incrementada.
CO2018003224A2 (es) Formulaciones de aminoacidos de liberacion modificada administradas oralmente
MX2015010139A (es) Composicion antiseptica oral para tratamiento de mucositis oral.
MX2015009269A (es) Composiciones farmaceuticas que comprenden donadores de nitroxilo.
MX2018002546A (es) Composiciones que comprenden un compuesto de urolitina.
EP4295909A3 (en) Carbidopa and l-dopa prodrugs and methods of use
EP4674433A3 (en) Pulsatile drug delivery system for treating morning akinesia
MX2017007840A (es) Compuestos de indenilo, composiciones farmaceuticas y usos medicos del mismo.
BR112016023899A2 (pt) composições compreendendo derivados de osteopontina para a inibição do crescimento do cabelo
MX2017015293A (es) Composicion para tratar lesiones tisulares.
MX372875B (es) Composiciones para el cuidado bucal que comprenden al menos un copolímero de fosfato / acrilato y al menos un ingrediente activo catiónico.
ECSP13012603A (es) Nueva formulacion del cetp(1)
GEP20186879B (en) Cycloalkyl-linked diheterocycle derivatives

Legal Events

Date Code Title Description
FG Grant or registration